Translate page

iCMLf Annual Report - what has the iCMLf accomplished in the last 12 months?

September 2014 - We are delighted to present the iCMLf Annual Report 2013/2014. It features the Foundation’s activities from Sept 1st 2013 to August 31st 2014.iCMLf Annual Report 2013 2014

Key outcomes from the iCMLf in the last 12 months include:

  • With 22 personalised preceptorships at 11 CML centres of excellence the iCMLf Clinical Preceptorship Program continues to have far reaching and long-term impact on the management of CML.
  • The iCMLf Diagnosis and Testing program to build local, sustainable capacity for CML diagnostics has been widely extended by funding 9 Phase I projects and 4 Phase II projects this year.
  • Visitors to the iCMLf website came from 80% of all countries around the world. With 130,000 page impressions per month and over 24,000 visitors per month the iCMLf website goes a long way to address
a global audience.
  • Cases in the interactive online Clinical Case Discussion Forum have had over 16,000 views this year.

New Structure and a Fresh Look: the iCMLf Website is relaunchedScreenshot Homepage 

August 2014 - The iCMLf has relaunched its website. Programs, discussions and education on this interactive platform now have a new structure and a fresh new look to make the multi-layered content more accessible. We invite you to see and look for yourself on a tour around the new website.

Truly global in focus - Interview with Timothy Hughes, chair of the iCMLf

NEW PHOTO Hughes T 02-mod2 Kopie 2

July 2014 - “We wanted to spread the benefit of new knowledge, effective drugs and accurate monitoring beyond the developed world. This was our first and is still our highest priority”. (Tim Hughes)

Q1: Great advances have been made in the management of patients with CML during the last couple of years. Where do you currently still see the biggest challenges and how could we best meet those challenges?

The outlook for a newly diagnosed CML patient is very positive in 2014 – a complete turnaround from the situation they faced even in the 1990s. However we still see CML patients transform into blast crisis in the first one or two years of kinase inhibitor therapy. We must find ways to identify these patients before they transform and trial innovative approaches. This remains one of our biggest challenges.

The inaugural iCMLf Goldman Prize is awarded to Professor RüdigerHehlmann Portraitfoto 2012 Hehlmann

February, 2014 - In addition to the Rowley Prize that the iCMLf awards annually to individuals that have made a major lifetime contribution to the understanding of the biology of CML, the iCMLf Directors have created a second prize. The recently launched Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. The new award has been created in memory of the late iCMLf chair to honour Professor Goldman´s commitment to clinical excellence in treating CML.

Dr J Apperley 2010

Professor Jane Apperley becomes a new member of the
iCMLf Board of Directors

April, 2014 - The iCMLf is delighted to announce that Professor Jane Apperley has accepted our invitation to join the iCMLf Board of Directors as a new member. “She is a leading expert in CML monitoring and management and has been a strong supporter of the Foundation through her work with preceptors at the Hammersmith Hospital”, said Tim Hughes, chair of the iCMLf.

The 2014 Rowley Prize is awarded toWitte head shot 1

Dr Owen N. Witte

February 2014 - In 2014 the iCMLf Rowley Prize for persons who have made major contributions to understanding the biology of CML is awarded to Dr Owen Witte, a Distinguished Professor of Microbiology, Immunology and Molecular genetics. Dr Witte is Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles (UCLA) and a Howard Hughes Medical Institute Investigator. He currently holds the UCLA Presidential Chair in Developmental Immunology.